Beacon Biomedical Inc. is a medical diagnostic development and a Centers of Medicare and Medicaid Services (CMS) CLIA accredited laboratory services company on a mission... to save as many lives as possible by providing easy, accurate and affordable blood tests for earlier cancer detection.
Our laboratory developed test (LDT) solutions are developed for healthcare practitioners and individuals alike and our intended to be used as screening test for the presence of undiagnosed cancer. They are specifically designed for those who are unwilling or unable to participate in cancer screening using current procedures and tests. Our focus is on providing blood-based cancer screening alternatives in order to improve screening participation and earlier detection of these devastating diseases.
It All Starts with An Idea
It’s a known fact that when cancer is detected earlier more lives are saved. If this is true, then why with all the billions of dollars being spent on patient education and awareness as to the life-saving benefits of routine cancer screening are we seeing 100's of thousands of people still dying each year from cancer? That question was the genesis behind Beacon Biomedical.
If our cancer screening tests are going to help save lives then they need to be optimize their adoption by doctors and patients alike... tests that are easy to administer and are minimally invasive to avoid any undue pain, discomfort and anxiety often associated with existing cancer screening tests. Our easy, accurate and affordable test uses a non-invasive sample of blood accomplishes this goal.
The right place for our tests is at the actual point-of-service and care. This is where it matters the most because it is here where the traditionally noncompliant patients can be best served and evaluated as to their risk of having undiagnosed cancer. And it is here, where proactive cancer healthcare discussions and follow-up monitoring, care & testing decisions can occur.
We focus on cancers that are associated with the higher mortalities, such as breast, colorectal and lung cancers. Over 65% of all the deaths in the U.S. associated with breast and colorectal cancers are associated with men and women who are not compliant with recommended cancer screening. Additionally, over 90% of all the deaths in the U.S. are associated with long-term smokers and ex-smokers. The common factor amongst these patients is noncompliance, which is why they will benefit most from our tests,
In order to provide the highest benefit possible, the tests we develop are designed specifically for those who are unwilling or unable to get screened using current tests and procedures being offered to them. Our simple blood test that can be drawn during any well check visit our routine blood work-up either at a doctor’s office or typical lab patient service center.